ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma

Activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL), the major constituent of nongerminal center B-cell-like (non-GCB) DLBCL, is associated with poorer survival outcomes than GCB-type DLBCL. In Phase II studies, lenalidomide combined with R-CHOP (R(2)-CHOP) improved outcomes relative t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Future Oncol
Main Authors: Nowakowski, Grzegorz S, Chiappella, Annalisa, Witzig, Thomas E, Spina, Michele, Gascoyne, Randy D, Zhang, Lei, Flament, Jocelyne, Repici, Jacqueline, Vitolo, Umberto
Formato: Artigo
Idioma:Inglês
Publicado em: Future Medicine Ltd 2016
Assuntos:
Clinical Trial Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5551933/
https://ncbi.nlm.nih.gov/pubmed/27089170
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2016-0130
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados